Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Barrow Hanley Credit Partners: Lens on Credit Series | Credit Markets: Then vs. Now

Credit Markets: Then vs. Now Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Credit Markets: Then vs. Now

Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies.

More about Chet Paipanandiker, Portfolio Manager

More about Nick Losey, Portfolio Manager

Video TranscriptExpand ↓

Yes the credit markets have been in a pretty interesting place over the last three years. We've basically been through a mini credit cycle. If you think back to what happened, go back to the early part of 2020, basically at a global pandemic. And by virtue of the Fed stepping in and helping to solve capital markets as well as work to develop a vaccine, we actually saw a credit markets do a complete about face. We started out with companies contemplating zero revenues and by the latter part of the year with the benefit of a vaccine, as well as with the benefit of companies terming out maturities and raising cash, basically enhancing their liquidity. You saw revenues come back and you saw companies with pretty pumped up liquidity facilities. So as a result, they were able to better handle the stresses that were occurring at the time, whether it's because of revenues, labor availability or inflation. At the same time, something else was happening to the consumer. You basically saw the consumer also see its balance sheet get pumped up by virtue of the stimulus checks that came through. And so pretty much you went through this period of extreme volatility where companies and consumers were in a bad place. They basically didn't about ship and everyone ended up in a generally better place from a fundamental perspective. And so what did that do with credit markets? We certainly saw a swoon to the downside when COVID occurred. Credit markets rebounded. As you went to the earlier part of this year, we ended into a period of new stress, basically Russia invading Ukraine. And it's interesting to see what happened to credit spreads during that time frame. So on a year to date basis, what you basically saw was double B's were underperforming because the Fed was raising rates. At the same time, credit risk was actually outperforming single B's and triple C's on a relative basis to double B's. But come April of 2022, they actually started to reverse, and you saw double B's start to outperform. And there was an indication that credit stress might actually be more of a concern on people's minds. And so you actually saw single B's and triple C's begin to underperform on a relative basis to double B's. What we are seeing in the credit markets today is, you know, something that we hadn't seen in a number of decades in the past. You know, when we think about what's going on in the environment right now, we came into the beginning of the year where inflation started to increase. And then with Russia, Russia invading Ukraine, basically that kind of added a spark to kind of really set the fire on inflation. And now we're sitting it roughly at 9% year over year inflation rate. We haven't really seen this type of inflation environment for upwards of four decades. So when you think about the investing world, there are not that many participants in the markets today that have actually directly experienced what we are experiencing now or are likely to experience if inflation stays at very high levels for the foreseeable future. Now, when we think about inflation, basically we were concerned about the inflationary environment going into the beginning of this year. So we really pulled back on our exposure to duration, longer duration assets and have benefited, because of that. Now we do not believe that we are going to run rate at a 9% inflation rate. You're already starting to see a lot of your data points tick over, but do not believe that we're going back to this one to 2% inflation rate environment.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com closed $220 million in equity and debt. It’s expanding its U.S. imaging network plus API-based scheduling and results delivery. For health plans and employers, imaging is starting to look like a platform procurement and integration decision, not a directory problem.

  • 01If imaging access is bought via an API, the real spec becomes integration depth: two-way scheduling plus results routing into the EMR, according to Business Wire.
  • 02Scan.com’s mix of $90M equity and $130M debt earmarked for M&A and working capital points to a fast-changing imaging provider network, which can help access but demands discipline in contracting and integration testing.
  • 03The same week’s funding news for Elucid ($55M) suggests AI imaging vendors will keep pushing toward FDA-cleared workflow insertions, a different buying path than network-layer platforms.

Sep 4, 2026

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitor messaging suggests compliance testing and AI-ready compute are becoming early decisions, not afterthoughts. Medical Economics described 2026 as a period shaped by rapid technological change, regulatory scrutiny and ongoing economic uncertainty. Medical Design & Outsourcing’s MD&M West 2026 preview points to exhibitors highlighting test equipment, contract manufacturing and other launch support services.

  • 01If a device roadmap includes AI features, the critical path shifts toward data and software evidence that regulators can audit, which means earlier lock-in of compute platforms and test plans, pulling verification and validation into supplier selection.
  • 02MD&M West exhibitor messaging suggests verification and validation capacity is becoming a procurement problem, with rentals and lab-ready gear positioned as a way to avoid booking delays and re-tests, according to Medical Design & Outsourcing.
  • 03With imaging and other new procedural and device concepts moving fast, manufacturing leaders should expect more frequent line-change decisions and component qualification work, as GE HealthCare's photon-counting CT CE mark reported by MedTech Dive and MDDI's New Technologies coverage illustrate.

Sep 3, 2026

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz brings 23+ years of experience as chief medical physicist at Texas Oncology and personal insight as a breast cancer survivor, enabling her to guide patient support groups and advocate for accessible cancer care. She emphasizes AI's potential in auto-contouring and treatment planning while stressing the need for proper training, validation, and transparency before implementation.

  • 01Over 23 years at Texas Oncology integrating personal cancer survivor experience with clinical expertise to improve patient empathy and support group leadership
  • 02AI in oncology requires human oversight, validation, and transparency; auto-contouring and auto-planning must be combined with staff training and rigorous protocol testing before deployment
  • 03Texas Oncology prioritizes offering state-of-the-art cancer treatments closer to home, including for rural patients, to reduce travel and ensure consistent, personalized care

Sep 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512